Cited by 410Lymphoma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsHematological disorders and diagnostics

The DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.

Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

Open access

Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., Verhoef, G.·2002·Annals of Oncology

DOI 10.1093/annonc/mdf256

Open this paper in CoChat — free account Open PDF

Abstract

Background Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.Patients and methods Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [(18)F]FDG-PET scan at midtreatment. Presence or absence of abnormal [(18)F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [(18)F]FDG-PET findings on PFS and OS.Results At midtreatment, 33 patients showed persistent abnormal [(18)F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [(18)F]FDG-PET findings and PFS (P <1 x 10(-5)) and OS (P <1 x 10(-5)). In multivariate analysis, [(18)F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 x 10(-7)) and OS (P <9 x 10(-6)) than the IPI (P <0.11 and P <0.03, respectively).Conclusions Early restaging [(18)F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdf256

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]
Harris, N. L., Jaffe, E., Stein, H., Pm, B., Jk, C., Cleary, M. L., Delsol, G., Peeters, C., Falini, B., & Gatter, K. C. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,312
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,950
Maximum Likelihood Reconstruction for Emission Tomography
Shepp, L. A., & Vardi, Y. (1982) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.1982.4307558 · Cited by 4,429
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
Jérusalem, G., Beguin, Y. P., Fassotte, M., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 562

Flagged first, then by citations

Show all 30 references

2 of the 30 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

2000, The first international symposium on biology and treatment of aggressive lymphomas. The stagnation seems to be over, Ann Hematol 2001, 80, B1

Sorted by citations

Items 301–400 of 410

Role of PET in lymphoma.
Schwaiger, M., & Wieder, H. A. (2005) · PubMed · Cited by 5
Stellenwert der PET/CT in der Lymphomdiagnostik
Afshar‐Oromieh, A., Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2012) · Der Radiologe · doi:10.1007/s00117-011-2255-2 · Cited by 4
Utilidad de la PET-TC en la valoración de la respuesta precoz al tratamiento en el linfoma B difuso de celula grande. Resultados preliminares
Romera, M. C., Cenzano, C. G., Caresia-Aróztegui, A. P., Martin-Comin, J., González-Barca, E. M., Brulles, Y. R., Abufón, A. P., Barba, J. R., Rodríguez-Bel, L., Rossi‐Seoane, S., et al. (2011) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2011.05.011 · Cited by 4
La place de la TEP au FDG dans l’évaluation des lymphomes
Bodet‐Milin, C., Salaün, P., Crespin, C., Vuillez, J.-P., & Kraeber‐Bodéré, F. (2009) · Médecine Nucléaire · doi:10.1016/j.mednuc.2009.06.005 · Cited by 4
Treatment of Diffuse Large B-Cell Lymphoma: A Risk-Based Approach
Sehn, L. H., & Connors, J. M. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.s.003 · Cited by 4
PET and PET/CT Imaging in Lymphoma
Jérusalem, G., Hustinx, R., & Rigo, P. (2006) · Springer eBooks · doi:10.1007/1-84628-187-3_9 · Cited by 4
FDG-PET Evaluation of Response to Treatment
Kostakoğlu, L. (2008) · PET Clinics · doi:10.1016/j.cpet.2008.09.001 · Cited by 4
Quantitative and qualitative evaluation of the interim PET/CT in lymphoma treatment in the prediction of complete metabolic response
Woll, J. P. P., Vicente, A. M. G., Rubio, M. P. T., Muñoz, A. P., Londoño, G. J., Martín, A. L., Primo, C. C., & Castejón, A. M. S. (2013) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2013.01.007 · Cited by 4
Évolution des critères d’évaluation de la réponse tumorale: apport de l’imagerie fonctionnelle
Ollivier, L., & Leclère, J. (2007) · ONCOLOGIE · doi:10.1007/s10269-007-0618-0 · Cited by 4
Normal and Abnormal Patterns of 18F-Fluorodeoxyglucose PET/CT in Lymphoma
Bar‐Shalom, R. (2006) · PET Clinics · doi:10.1016/j.cpet.2006.04.002 · Cited by 4
Diffuse Large B-Cell Lymphoma
Jardin, F., & Tilly, H. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-408-1_11 · Cited by 3
PET imaging in lymphoma
Hutchings, M. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.21 · Cited by 3
Optimization of metabolic criteria in the prognostic assessment of patients with lymphoma. A multicenter study
Cozar, M., García-Garzón, J. R., Moragas-Freixa, M., Soler-Peter, M., Massanas, P. B., Sánchez-Delgado, M., Jurado, R. S., Aguilar-Barrios, J. E., Llorens, R. S., & Ferrer-Rebolleda, J. (2017) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2017.06.006 · Cited by 3
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma
Friend, B. D., Muhsen, I. N., Patel, S., Hill, L. C., Lulla, P., Ramos, C. A., Pingali, S. R., Kamble, R. T., John, T. D., Salem, B. M., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01599-5 · Cited by 3
FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma
Hutchings, M., & Barrington, S. F. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0134-y · Cited by 3
Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology;May 31 to June 3, 2003 Chicago, Illinois
Klem, J., Maung, K., Gibson, A. D., & Jain, V. K. (2003) · Clinical Lymphoma · doi:10.1016/s1526-9655(11)70012-4 · Cited by 3
PET and PET/CT in Management of the Lymphomas
Podoloff, D. A., & Macapinlac, H. A. (2006) · PET Clinics · doi:10.1016/j.cpet.2006.04.003 · Cited by 3
FDG PET and alternative imaging in the management of thyroid carcinoma.
AL-NAHHAS, A. M. (2003) · PubMed · Cited by 3
Prognostic Role of Interim 18-Fluorodeoxyglucose-PET in Diffuse Large B Cell Lymphoma: Experience from a Tertiary Care Centre in North India
Kumar, S., Gupta, A., Ora, M., Rahman, K., Sanjeev, Choudhary, R., & Nityanand, S. (2021) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-021-01441-w · Cited by 2
Recommendations to stage and assess the response to therapy of lymphomas with [18F]FDG-PET-CT
Barrington, S. F., Fosse, P., Withofs, N., Itti, E., Hustinx, R., Couturier, O., & Meignan, M. A. (2016) · Médecine Nucléaire · doi:10.1016/j.mednuc.2015.12.004 · Cited by 2
Molecular Imaging in Early Therapy Monitoring
Klutmann, S., & Stahl, A. R. (2008) · Elsevier eBooks · doi:10.1016/b978-012374212-4.50008-0 · Cited by 2
Treatment approach to diffuse large B-cell lymphomas
Smith, S. M., & Vose, J. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781926.016 · Cited by 2
Diagnostic and Treatment Response Imaging in Lymphomas
Wu, X., & Kellokumpu-Lehtinen, P.-L. (2012) · InTech eBooks · doi:10.5772/31800 · Cited by 2
Positron Emission Tomography (PET) in Germ Cell Tumors (GCT)
Santis, M. D., Maj‐Hes, A., & Bachner, M. (2008) · Springer eBooks · doi:10.1007/978-1-84628-759-6_28 · Cited by 2
Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL
Song, M.-K., Chung, J. S., Kim, S., Kim, S. S., & Shin, H. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2311-5 · Cited by 2
Evaluación cuantitativa y cualitativa de la PET/TC a mitad del tratamiento en linfomas en la predicción de respuesta metabólica completa
Woll, J. P. P., Vicente, A. M. G., Rubio, M. P. T., Muñoz, A. P., Londoño, G. J., Martín, A. L., Primo, C. C., & Castejón, A. M. S. (2012) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2012.03.003 · Cited by 2
Malignant B‐cell Lymphoma, WHO Classification and the Respective 18F‐fluoro‐deoxy‐glucose Positron Emission Tomography Results
Hoffmann, M., & Raderer, M. (2007) · Imaging Decisions MRI · doi:10.1111/j.1617-0830.2007.00084.x · Cited by 2
18F-FDG small animal PET for early detection of human anaplastic large cells lymphoma xenograft in immunocompromised mice.
Ambrosini, V., Quarta, C., Zinzani, P. L., Fini, M., Giavaresi, G., Torricelli, P., Malvi, D., Nanni, C., Grassetto, G., Rubello, D., et al. (2008) · PubMed · Cited by 2
Adults with Palpable Neck Mass: Evidence-Based Neuroimaging
Learned, K. O., Malloy, K. M., Langer, J. E., & Loevner, L. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-3320-0_39 · Cited by 2
A picture is worth a thousand words: a history of diagnostic imaging for lymphoma
Wijetunga, N. A., Imber, B. S., Caravelli, J. F., Mikhaeel, N. G., & Yahalom, J. (2021) · British Journal of Radiology · doi:10.1259/bjr.20210285 · Cited by 2
Positron Emission Tomography and Cancer
Chatzifotiadis, D., Buchanan, J. W., & Wahl, R. L. (2007) · Springer eBooks · doi:10.1007/0-387-31056-8_33 · Cited by 2
Utilidad de la deoxiglucosa marcada con flúor-18 (FDG) en el manejo de los linfomas
Massardo, T., José Canessa, G., M, M. J. J., Patricio González, E., Pamela Humeres, A., & Paulina Sierralta, G. (2006) · Revista médica de Chile · doi:10.4067/s0034-98872006000700016 · Cited by 2
Hodgkin’s Disease and Lymphomas
Kostakoğlu, L., Coleman, M., & Goldsmith, S. J. (2008) · Springer eBooks · doi:10.1007/978-3-540-28026-2_16 · Cited by 2
Nuclear Medicine
Jérusalem, G., & Hustinx, R. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0081-9.50015-7 · Cited by 2
International staging and response criteria for lymphomas
Cheson, B. D. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781926.015 · Cited by 1
Imaging of Tumour Metabolism: 18-FDG PET
Lin, M. F., & Kumar, D. (2013) · Springer eBooks · doi:10.1007/978-3-642-40412-2_9 · Cited by 1
Évaluation de la réponse au traitement du lymphome avec la TEP 18F-FDG : existe-t-il un consensus dans l’évaluation de la réponse ?
Bolton, R. C. D., & Delgado, J. L. C. (2010) · Médecine Nucléaire · doi:10.1016/j.mednuc.2010.07.018 · Cited by 1
COMPROMISO MUSCULAR POR LINFOMA NO HODGKIN: CASO CLÍNICO Y REVISIÓN DEL TEMA
Pablo Avaria, P., Claudia Ortega, M., Rossana Pruzzo, C., Alejandra Pizarro, G., & Horacio Amaral, P. (2010) · Revista de Fomento Social · doi:10.4067/s0717-93082010000200003 · Cited by 1
Late Clinically Silent Perforation of Intestinal Non-Hodgkin's Lymphoma
Kotb, R. R., Turcotte, É. E., Fadden, N. M., Gomes, M. M., Sawan, B., & Schmutz, G. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.030 · Cited by 1
Radiographic Diagnosis and Staging
Santis, M. D., Bachner, M., Lawrentschuk, N., Jack, G. S., & Bolton, D. M. (2010) · Springer eBooks · doi:10.1007/978-1-84800-370-5_4 · Cited by 1
Diagnostic Applications of Nuclear Medicine: Lymphomas
Hughes, N., Jacene, H. A., Tirumani, S. H., & Wahl, R. L. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_7-2 · Cited by 1
Diagnostic Applications of Nuclear Medicine: Lymphomas
Hughes, N., Jacene, H. A., Tirumani, S. H., & Wahl, R. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_7 · Cited by 1
Development of a model to predict Ki-67 expression status in non-Hodgkin’s lymphoma based on PET radiomics
Tian, K., Tong, P., Wu, K., Azhar, A., Fang, Y., Xu, N., & Wang, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1567152 · Cited by 1
PET-CT Imaging of Lymphoma
Kostakoğlu, L. (2010) · Springer eBooks · doi:10.1007/978-0-387-48902-5_22 · Cited by 1
Hematologic Malignancy
Vinnicombe, S., Reznek, R. H., & Rohatiner, A. Z. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2232-1.00029-2 · Cited by 1
Oncology—Lymphoma
(2005) · Springer eBooks · doi:10.1007/1-84628-100-8_14 · Cited by 1
FDG-PET Scanning in Lymphoma and Lymphoma of the Thyroid
McDougall, I. R. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-995-0_79 · Cited by 1
FDG-PET scans in patients with lymphoma
Elstrom, R., & Leonard, J. P. (2008) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-008-0028-4 · Cited by 1
Wertigkeit der F-18-FDG-PET in der Diagnostik des malignen Lymphoms
Sciuk, J., Hermann, S., & Franzius, C. (2002) · Der Radiologe · doi:10.1007/s00117-002-0833-z · Cited by 1
Comparaison de l’IRM de diffusion et de la TEP/TDM au FDG dans le bilan des lymphomes
Bouharati-Moussa, K., Papathanassiou, D., Benaïssa, A., Portefaix, C., Bruna-Muraille, C., Delmer, A. J., Kolb, B., Liehn, J., & Marcus, C. D. (2012) · Médecine Nucléaire · doi:10.1016/j.mednuc.2012.06.010 · Cited by 1
Front-Line Therapy For Nonlocalized Diffuse Large B-Cell Lymphoma: What Has Been Demonstrated and What Is Yet To Be Established
Brusamolino, E., Maffioli, M., Bonfichi, M., & Vitolo, U. (2008) · Future Oncology · doi:10.2217/14796694.4.2.199 · Cited by 1
Diagnostic Radiology
Vinnicombe, S., & Reznek, R. H. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0081-9.50014-5 · Cited by 1
FDG-PET and radiotherapy in lymphoma
Ricardi, U., Specht, L., Versari, A., & Berthelsen, A. K. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0129-8
The role of positron emission tomography in T-cell lymphoma and T-cell specific response criteria
Cheson, B. D. (2009) · Hematology Meeting Reports (formerly Haematologica Reports) · doi:10.4081/hmr.v3i1.524
Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs
Boss, D. S. (2009) · Utrecht University Repository (Utrecht University)
PET – Assessment of Oncologic Treatment Response
Inga, S., & Victor, S. (2013) · InTech eBooks · doi:10.5772/57127
Nodal aggressive non-Hodgkin’s lymphoma in the adult: a review article
Martelli, M., Corradini, P., Santo, A., Gaïdano, G., Gianni, A. M., Musto, P., Pileri, S. A., Rambaldi, A., Zinzani, P. L., & Tura, S. (2005) · Hematology Meeting Reports (formerly Haematologica Reports) · doi:10.4081/hmr.v1i12.355
Szintigraphie und Single-Photon-Emissions-Computertomographie (SPECT und PET)
Knapp, W. H. (2009) · Der Onkologe · doi:10.1007/s00761-009-1608-1
Prognostic Factors in Pediatric Classical Hodgkin Lymphoma: Concepts, Questions and Perspectives
Barros, M. H. M., Morais, A., de Morais, V. L. L., Hassan, R., & Muniz, M. T. C. (2010) · DergiPark (Istanbul University) · doi:10.17334/jps.14790
Aggressive B-cell Lymphomas : Studies of Treatment, FDG-PET Evaluation and Prognostic Factors
Adde, M. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Utility of Positron Emission Tomography Imaging in Lymphoma: A Clinician's Point of View
Apostolidis, J. P. (2010) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v5i3.207
Lymphoma
Kostakoglu, L. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139026543.015
Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma
Schneider, T. J., Molnár, Z., Deák, B., Várady, E., Tóth, E., Csomor, J., Matolcsy, A., Lövey, J., Lengyel, Z., Petri, K., et al. (2009) · Orvosi Hetilap · doi:10.1556/oh.2009.28726
Tumor Metabolic Phenotypes on 18F FDG PET
Wong, C.-Y. O., & Khong, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.061010
The Role of Imaging in Malignant Lymphoma: A Critical View on PET Scanning in Current Clinical Practice
Namberger, K., & Greil, R. (2007) · Imaging Decisions MRI · doi:10.1111/j.1617-0830.2007.00085.x
The Use of Positron Emission Tomography with [18F] 2-Fluoro-d-2-Deoxyglucose (FDG-PET) in Hodgkin and Non-Hodgkin's Lymphoma
Chiusolo, P., Sica, S., & Leone, G. G. M. (2003) · Hematology · doi:10.1080/1024533032000158841
Early treatment intensification for aggressive non-Hodgkin's lymphoma
Swinnen, L. J. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000239877.93344.bc
La place de la TEP au FDG dans l’évaluation des lymphomes en 2012
Bodet‐Milin, C., Eugène, T., Gastinne, T., Bailly, C., Gouill, S. L., Dupas, B., & Kraeber‐Bodéré, F. (2013) · Journal de radiologie diagnostique et interventionnelle · doi:10.1016/j.jradio.2012.12.002
Intérêt de la TEP au 18F-FDG préthérapeutique pour prédire la réponse à la radio-immunothérapie dans les lymphomes non hodgkiniens
Cazaentre, T., Morschhauser, F., Vermandel, M., Betrouni, N., Prangère, T., Petyt, G., Steinling, M., & Huglo, D. G. (2010) · Médecine Nucléaire · doi:10.1016/j.mednuc.2010.10.004
Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin’s lymphomas: is it too easy to be true?
Balzarotti, M., Magagnoli, M., & Santoro, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg283
Recent advances in the treatment of B-cell lymphoma
Habermann, T. M. (2009) · F1000 Medicine Reports · doi:10.3410/m1-13
The role of FDG-PET in the interim evaluation of therapy response in diffuse large B-cell lymphoma
Ellmann, A. V. Z. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.05.023
From: 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006, Orlando, FL
Reddy, G. K., Gupta, M., Shivakumar, L., Jaganath, S., Lonial, S., Mughal, T. I., & Abbott, B. L. (2007) · Clinical Lymphoma & Myeloma · doi:10.1016/s1557-9190(11)70058-0
Mixed Response in Interim Positron Emission Tomography/Computed Tomography Leads to Detection of a Gastrointestinal Stromal Tumor in a Patient With Mediastinal Diffuse Large B-Cell Lymphoma
Rehmsmeier, C., Keßler, T., Koschmieder, S., Ross, M., Weckesser, M., Weßling, J., Koehler, G., & Berdel, W. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8848
Experimental and clinical validation of positron emission tomography in the therapy evaluation of lymphomas.
Geneeskunde, F. (2003)
Thoracic Involvement in Non-Hodgkin Lymphoma
DiPiro, P. J., & Costello, P. (2004) · Medical radiology · doi:10.1007/978-3-642-18832-9_7
Optymalizacja i indywidualizacja leczenia ch‡oniaka Hodgkina z wykorzystaniem wczesnego badania PET Optimization and individualization of treatment based on interim PET result in patients with Hodgkin lymphoma
Zaucha, J. M. (2011)
An Overview of the Clinical Evaluation of Lymphomas According to the WHO 2008 Classification
Vassilakopoulos, T. P., & Vrakidou, E. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-27380-8_4
Functional Imaging in Image-Guided Radiation Th erapy Treatment Planning: Th e Next Big Step in Lymphoma Radiotherapy
Sharma, N., & Macklis, R. M. (2013) · CRC Press eBooks · doi:10.3109/9781420058758-3
Oblimersen Sodium in Previously Treated Patients (n = 16) Response Oblimersen Sodium + R-CHOP in Previously Untreated Patients (n = 7)*
Saha, O. (2003)
Treatment of B-cell lymphomas
Stathis, A., & Doǧan, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-08467-1_6
PET/CT in Lymphoma and Lymphoma of the Thyroid
McDougall, I. R., & Iagaru, A. H. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3314-3_93
Diagnostic Applications of Nuclear Medicine: Lymphomas
Jacene, H. A., Tirumani, S. H., & Wahl, R. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-26236-9_7
Lymphoma: Diagnostic and Therapeutic Applications of Radiopharmaceuticals
Delaloye, A. B. (2010) · Springer eBooks · doi:10.1007/978-88-470-1637-8_27
Wertigkeit der F-18-FDG-PET in der Diagnostik des malignen Lymphoms
Lymphome, M. (2002)
The Approach to the Patient with Malignant Lymphoma
Cheson, B. D. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0081-9.50012-1
Lymphomes : principes thérapeutiques et imagerie post-thérapeutique
Hérin, E., Chalaye, J., Lagrange, J., Belhadj, K., de Kerviler, É., Luciani, A., Rahmouni, A., & Itti, E. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-73840-1.00014-9
18F-FDG-PET/CT for Evaluation of treatment response in high grade lymphoma
Kumar, Y. A., Rakesh, K., Arun, M., & Sharma, A. (2017) · Nepalese Journal of Cancer · doi:10.3126/njc.v1i1.25631
Lymphoma
Esiashvili, N., Anderson, C. M., Kahn, S., & HALKAR, R. K. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3224-3.50015-3
Lymphoma: Management Using PET/CT
Schaefer, N. G. (2014) · Springer eBooks · doi:10.1007/978-88-470-5659-6_34
Current Awareness in Hematological Oncology
(2003) · Hematological Oncology · doi:10.1002/hon.706
Lymphomas
Jacene, H. A., & Wahl, R. L. (2012) · Springer eBooks · doi:10.1007/978-0-387-48894-3_7
Lymphomes
Bodet‐Milin, C., Itti, E., & Salaün, P. (2019) · Médecine Nucléaire · doi:10.1016/j.mednuc.2018.12.016
Diagnostic Applications of Nuclear Medicine: Lymphomas
Jacene, H. A., Tirumani, S. H., & Wahl, R. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-26067-9_7-1
Hodgkin Lymphoma
Portlock, C. S., Kumar, A. A., & Armitage, J. O. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm119
Hematologic Malignancy: The Lymphomas
Vinnicombe, S., & Garg, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69538-1.00030-6
Malignant Lymphomas
Menzel, C. (2004) · Springer eBooks · doi:10.1007/978-3-642-18803-9_26
Lymphome
Mohnike, W., Hör, G., & Schelbert, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-17805-4_11
Lymphome
(2006) · Springer eBooks · doi:10.1007/3-540-31215-3_9
In Reply:
Horning, S. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.313

Authors: Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G.
Affiliations: Universitair Ziekenhuis Leuven (BE)
Corresponding author: Spaepen, K.
ORCID: Stroobants, S.
Dupont, P.
Vandenberghe, P.
Thomas, J.
Balzarini, J.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2002-09
Volume: 13
Issue: 9
Pages: 1356-1363
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdf256
OpenAlex: W1990827442
Cited by: 410
References: 30
Citations by year: 2026: 2 · 2025: 1 · 2023: 3 · 2022: 11 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 2 · 2017: 15 · 2016: 18 · 2015: 17 · 2014: 14 · 2013: 25 · 2012: 25
FWCI: 12.74
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 6337 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Fonds Wetenschappelijk Onderzoek
Topics: Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Hematology › Hematological disorders and diagnostics
Keywords: aggressive non-Hodgkin lymphoma, 18F-FDG PET, treatment response prediction, progression-free survival, overall survival, International Prognostic Index, complete remission, prognostic factors, treatment response monitoring
MeSH terms: Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Cyclophosphamide, Doxorubicin, Evaluation Studies as Topic, Female, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Monitoring, Physiologic, Neoplasm Staging, Predictive Value of Tests, Prednisolone, Probability, Prognosis, Prospective Studies, Sensitivity and Specificity, Time Factors, Tomography, Emission-Computed, Vincristine, Survival Rate, Multivariate Analysis, Treatment Outcome, Fluorodeoxyglucose F18

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks